# In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients

> **NCT04196608** · — · UNKNOWN · sponsor: **Emilio Bouza** · enrollment: 1005 (estimated)

## Conditions studied

- Ceftolozane/Tazobactam
- Imipenem/Relebactam
- Hematology and Oncology

## Interventions

- **DRUG:** Ceftolozane/tazobactam
- **DRUG:** imipenem- relebactam

## Key facts

- **NCT ID:** NCT04196608
- **Lead sponsor:** Emilio Bouza
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-01
- **Primary completion:** 2020-05-31
- **Final completion:** 2020-09-30
- **Target enrollment:** 1005 (ESTIMATED)
- **Last updated:** 2019-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04196608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04196608, "In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04196608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*